PDL Biopharma's Fair Q4: Fool by Numbers

Recs

16

On Feb. 21, PDL BioPharma (Nasdaq: PDLI) released fourth-quarter earnings for the period ended Dec. 31.

  • Revenues rose 29%, backed by a 31% growth in royalties and a 23% growth in sales of products.
  • Net loss has widened, primarily due to asset impairment charges to the tune of $72.1 million related to the company's Retavase product.
  • Cash flow generated from operating activities for fiscal 2006 was $78.8 million, compared with $31.6 million for the full year 2005.
  • The company anticipates total revenues for fiscal 2007 to be around $450 million-$500 million and non-GAAP EPS of $0.38 to $0.54.
  • PDL Biopharma is highly regarded in Motley Fool CAPS, sporting a four-star rating.

(Figures in thousands, except per-share data)

Income Statement Highlights

Q4 2006

Q4 2005

Change

Sales

$107,842

$83,653

28.9%

Net Profit

($89,708)

($34,096)

N/A

EPS

($0.78)

($0.31)

N/A

Diluted Shares

114,403

111,571

2.5%



Get back to basics with a look at the income statement.

Margin Checkup

Q4 2006

Q4 2005

Change*

Gross Margin

77.4%

80.0%

(2.6)

Operating Margin

(84.4%)

(42.0%)

(42.4)

Net Margin

(83.2%)

(40.8%)

(42.4)

*Expressed in percentage points.

Margins are the earnings engine. See how they work.

Balance Sheet Highlights

Assets

Q4 2006

Q4 2005

Change

Cash + ST Invest.

$426,285

$333,922

27.7%

Accounts Rec.

No Data

No Data

No Data

Inventory

No Data

No Data

No Data



Data for liabilities not available.

Learn the ways of the balance sheet.

Cash Flow Highlights

2006

2005

Change

Cash From Ops.

$78,770

$31,550

149.7%

Capital Expenditures

No Data

No Data

N/A

Free Cash Flow

No Data

No Data

N/A



Find out why Fools always follow the money.

Related Companies:

  • Genentech (NYSE: DNA)
  • Medicines Co. (Nasdaq: MDCO)
  • Medarex (Nasdaq: MEDX)
  • Elan (NYSE: ELN)
  • Millennium Pharmaceuticals (Nasdaq: MLNM)

Related Foolishness:

PDL Biopharma and Millennium Pharmaceuticals are Rule Breakers recommendations. Keep tabs on big events in tiny technology with a free 30-day trial subscription to David Gardner's Motley Fool Rule Breakers.

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 522436, ~/articles/ArticleHandler.aspx, 7/6/2009 2:19:27 AM

Keep Reading:

“PDL Biopharma's Fair Q4: Fool by Numbers”

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Get involved! »

Most Recent

Jul 2 at 4:22 PM

Market Summary

DJIA 8,280.74 -223.32 -2.63%
S&P 500 896.42 -26.91 -2.91%
NASD 1,796.52 +0.00 +0.00%
Sponsored by:

Related Tickers

PDL BioPharma, Inc.

CAPS Rating 3/5 Stars

$7.98

-0.03 (-0.37%)

Outperform541

Underperform36

Rate This Stock